Literature DB >> 12210291

Coffin-Lowry syndrome: a 20-year follow-up and review of long-term outcomes.

Alasdair G W Hunter1.   

Abstract

The Coffin-Lowry syndrome has become well established since the first report of affected patients by Coffin et al. [1966: Am J Dis Child 112:205-213]. Since that time over a hundred cases have been reported and the responsible gene has been identified. However, there remains a paucity of long-term follow-up information on older patients with which to counsel affected families about prognosis. There is also much to be learned about genotype-phenotype correlations. In 1982 we reported 12 patients (including carrier mothers) from eight families, one of whom had died about the time the paper was written. Recently, we have been able to obtain follow-up information on six of the affected patients and one of the carrier mothers. A number of important complications have occurred, including premature death, loss of ambulation, and quadriplegia. This paper updates the medical histories of our patients and summarizes the clinically important complications that have been reported in patients with Coffin-Lowry syndrome. There are few data on patients over the age of 30, and much more longer term follow-up is required. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 12210291     DOI: 10.1002/ajmg.10574

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  13 in total

1.  Recurrent Nonconvulsive Status Epilepticus in a Patient with Coffin-Lowry Syndrome.

Authors:  Markus Gschwind; Giovanni Foletti; Alessandra Baumer; Armand Bottani; Jan Novy
Journal:  Mol Syndromol       Date:  2015-05-19

2.  p90 ribosomal S6 kinase 2 exerts a tonic brake on G protein-coupled receptor signaling.

Authors:  Douglas J Sheffler; Wesley K Kroeze; Bonnie G Garcia; Ariel Y Deutch; Sandra J Hufeisen; Patrick Leahy; Jens C Brüning; Bryan L Roth
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-10       Impact factor: 11.205

3.  The Coffin-Lowry syndrome-associated protein RSK2 regulates neurite outgrowth through phosphorylation of phospholipase D1 (PLD1) and synthesis of phosphatidic acid.

Authors:  Mohamed-Raafet Ammar; Yann Humeau; André Hanauer; Bernard Nieswandt; Marie-France Bader; Nicolas Vitale
Journal:  J Neurosci       Date:  2013-12-11       Impact factor: 6.167

4.  ATF4 mediation of NF1 functions in osteoblast reveals a nutritional basis for congenital skeletal dysplasiae.

Authors:  Florent Elefteriou; M Douglas Benson; Hideaki Sowa; Michael Starbuck; Xiuyun Liu; David Ron; Luis F Parada; Gerard Karsenty
Journal:  Cell Metab       Date:  2006-12       Impact factor: 27.287

Review 5.  Coffin-Lowry syndrome.

Authors:  Patricia Marques Pereira; Anne Schneider; Solange Pannetier; Delphine Heron; André Hanauer
Journal:  Eur J Hum Genet       Date:  2009-11-04       Impact factor: 4.246

6.  Mitral and tricuspid valve surgery for Coffin-Lowry syndrome.

Authors:  Takeshi Yoshida; Takeki Ohashi; Masato Furui; Souichirou Kageyama; Noriko Kodani; Yutaka Kobayashi; Yasutaka Hirai; Reo Sakakura
Journal:  Gen Thorac Cardiovasc Surg       Date:  2013-07-20

7.  Mechanical ventilation in Coffin-Lowry syndrome: a case report.

Authors:  Edmilson Bastos de Moura; Érica Leal Teixeira de Moura; Fábio Ferreira Amorim; Vânia Maria Oliveira
Journal:  Rev Bras Ter Intensiva       Date:  2016 Oct-Dec

8.  RSK3 is required for concentric myocyte hypertrophy in an activated Raf1 model for Noonan syndrome.

Authors:  Catherine L Passariello; Eliana C Martinez; Hrishikesh Thakur; Maria Cesareo; Jinliang Li; Michael S Kapiloff
Journal:  J Mol Cell Cardiol       Date:  2016-03-03       Impact factor: 5.000

9.  The natural history of spinal deformity in patients with Coffin-Lowry syndrome.

Authors:  M Welborn; S Farrell; P Knott; E Mayekar; S Mardjetko
Journal:  J Child Orthop       Date:  2018-02-01       Impact factor: 1.548

Review 10.  The Changing Landscape in the Genetic Etiology of Human Tooth Agenesis.

Authors:  Meredith A Williams; Ariadne Letra
Journal:  Genes (Basel)       Date:  2018-05-16       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.